Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
127 stopped studies mapped to Malignant Endometrial Neoplasm and descendants · 87% state a reason
Over the 127 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase 1 | terminated | Nov 4, 2021 | Nurix Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial… | Phase 2 | withdrawn | Sep 21, 2023 | Genmab | Enrollment challenged by availability of other treatment options | Enrollment / accrual |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial… | — | terminated | May 26, 2023 | Wake Forest University Health Sciences | This was a national survey of physicians. Per the protocol, they were only allowed to be contacted… | Other (stated, no rule matched) |
| NCT05390021 | PET/MRI in Endometrial Cancer | N/A | withdrawn | May 25, 2022 | Massachusetts General Hospital | Unable to enroll patients to study | Enrollment / accrual |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage… | Phase 2 | terminated | Feb 8, 2021 | Henry Ford Health System | Low accrual | Enrollment / accrual |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With… | Phase 1 | terminated | Oct 14, 2020 | Haihe Biopharma Co., Ltd. | Business decision | Sponsor / business decision |
| NCT04970368 | Comparison of Nodal Staging in Endometrial Cancer | Phase 3 | terminated | Jul 21, 2021 | Frederick R. Ueland, M.D. | Slow accrual | Enrollment / accrual |
| NCT00250016 | Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) | — | withdrawn | Nov 7, 2005 | University of New Mexico | UNM did not proceed with research | Other (stated, no rule matched) |
| NCT03694834 | Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer | Early Phase 1 | terminated | Oct 3, 2018 | UNC Lineberger Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05332483 | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer(MA-EEC) | Phase 1 | terminated | Apr 18, 2022 | Sunnybrook Health Sciences Centre | Slow enrollment | Enrollment / accrual |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients… | Phase 3 | withdrawn | Feb 6, 2023 | EQRx International, Inc. | The study is being closed based on corporate changes at EQRx and is not related to any efficacy or… | Safety / toxicity |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk… | Phase 2 | terminated | Dec 30, 2009 | Albert Einstein College of Medicine | Due to slow accrual. Results from the PORTEC3 the study rendered the hypothesis no longer valid. | Enrollment / accrual |
| NCT04511026 | Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in… | Phase 2 | terminated | Aug 12, 2020 | Stanford University | Efficacy | Efficacy / futility |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating… | Phase 2 | terminated | Apr 14, 2014 | Albert Einstein College of Medicine | Low accrual. Study formally terminated by PI on 12/1/2017 | Enrollment / accrual |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA… | — | terminated | Nov 25, 2013 | University of Washington | not stated | Not stated |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | Phase 2 | terminated | Aug 22, 2018 | Donna Hammond, PhD | Enrollment challenges | Enrollment / accrual |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors… | Phase 2 | withdrawn | Jun 15, 2022 | Haider Mahdi | Slow Accrual | Enrollment / accrual |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian… | Phase 1 | withdrawn | Apr 21, 2014 | Rutgers, The State University of New Jersey | Research cancelled | Other (stated, no rule matched) |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | Phase 2 | terminated | Mar 13, 2017 | Xenetic Biosciences, Inc. | The study was discontinued due to a change in development strategy and not due safety concern. | Safety / toxicity |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03324958 | VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for…(Vire-Brachy) | N/A | terminated | Oct 30, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Enrollment difficulties | Enrollment / accrual |
| NCT03945786 | Diagnostic Performance of Hybrid PET/MRI in the Staging of Endometrial Carcinoma | — | suspended | May 10, 2019 | Xuanwu Hospital, Beijing | Recuriting inclusion and exclusion criteria will be changed as COVID-19. | COVID-19 / pandemic |
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic… | Phase 2 | terminated | May 13, 2009 | PharmaMar | Slow and poor recruitment. | Enrollment / accrual |
| NCT02127151 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer(PANDA) | Phase 2 | withdrawn | Apr 30, 2014 | University College, London | Withdrawal of Industry support for the study | Other (stated, no rule matched) |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | University of Chicago | The study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed… | Phase 2 | terminated | Feb 2, 2006 | Carilion Clinic | Investigator abruptly left Carilion. | Investigator |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal… | Phase 1 / Phase 2 | withdrawn | Apr 1, 2010 | Imperial College London | Failure to recruit. | Enrollment / accrual |
| NCT04197219 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | Phase 2 | withdrawn | Dec 13, 2019 | Case Comprehensive Cancer Center | PI is leaving institution | Other (stated, no rule matched) |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | Phase 1 | terminated | Jun 22, 2015 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | not stated | Not stated |
| NCT01939028 | Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery | N/A | terminated | Sep 11, 2013 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03115593 | Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for… | N/A | withdrawn | Apr 14, 2017 | Brugmann University Hospital | Lack of human ressources | Other (stated, no rule matched) |
| NCT02665962 | Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative… | N/A | terminated | Jan 28, 2016 | Abramson Cancer Center at Penn Medicine | Poor enrollment | Enrollment / accrual |
| NCT03466034 | The Role of Hypoxia as a Selective Pressure for TP53 Mutations | — | terminated | Mar 15, 2018 | Institute of Cancer Research, United Kingdom | Low numbers of eligible patients and failure to successfully recruit them. | Enrollment / accrual |
| NCT00394602 | Chemoradiation-Induced Nausea and Emesis: Quality of Life | — | terminated | Nov 1, 2006 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure due to slow/insufficient accrual. | Enrollment / accrual |
| NCT02566811 | Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)(STATEC) | N/A | terminated | Oct 2, 2015 | University College, London | Withdrawal of funding by CR UK due to poor recruitment | Enrollment / accrual |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With… | Phase 3 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | Study drug no longer available resulting in lack of study drug for participants. | Other (stated, no rule matched) |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Phase 2 | withdrawn | Feb 11, 2019 | University of Oklahoma | Study was not initiated. | Other (stated, no rule matched) |
| NCT02558348 | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial,…(AL3818) | Phase 1 / Phase 2 | terminated | Sep 24, 2015 | Advenchen Laboratories, LLC | Sponsor termination | Other (stated, no rule matched) |
| NCT02907073 | Positron Emission Tomography (PET) Imaging Studies With NIS Reporter | Phase 1 / Phase 2 | terminated | Sep 20, 2016 | Mayo Clinic | pursuing IND | Other (stated, no rule matched) |
| NCT01251354 | Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy | Phase 2 | terminated | Dec 1, 2010 | Ipsen | The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 19, 2024source: clinicaltrials